Madhavan Balachandran Sells Shares of uniQure N.V.
Madhavan Balachandran sold 11,685 shares of uniQure N.V. on June 17, 2026.
Key Points
- Madhavan Balachandran sold 11,685 shares of uniQure N.V. on June 17, 2026, with shares trading at $46.37 on Monday.
- uniQure N.V. has a market cap of $2.92 billion and a forward P/E ratio of -15.58, indicating it's not currently profitable.
- Analysts from Barclays, Goldman Sachs, and others have set varied price targets, with a consensus rating of 'strong buy'.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Madhavan Balachandran, an insider at uniQure N.V. (NasdaqGS: QURE), sold 11,685 shares of the company on June 17, 2026. The stock was trading at $46.37 on Monday.
Insider Buying and Selling at uniQure N.V.
On June 17, 2026, Madhavan Balachandran sold 11,685 shares of uniQure N.V. Other insider activity includes CEO Matthew Kapusta selling 41,671 shares at $50.00 on June 18, 2026, under a pre-planned trading arrangement. On the same day, Kapusta also bought 4,656 shares at $31.71.
Other Institutional Activity in uniQure N.V.
Several institutional investors adjusted their positions in uniQure. AVORO Capital Advisors LLC reduced its holdings by 190,405 shares to a total of 5,959,595 shares, valued at approximately $97.4 million, marking a 3.1% decrease. Meanwhile, Aberdeen Group PLC increased its holdings by 1,627,746 shares, resulting in a 44.2% increase, bringing its total to 5,306,386 shares worth about $86.8 million. Two Sigma Investments, LP significantly increased its stake by 1,224,587 shares, an 84.4% rise, to hold 2,675,871 shares valued at $43.8 million.
uniQure N.V. Stock Down 6.1%
Shares of uniQure N.V. (NasdaqGS: QURE) traded near $46.37 on Monday. The company has a market capitalization of $2.92 billion and a forward P/E ratio of -15.58, reflecting its current lack of profitability. The stock's 52-week range is between $8.73 and $71.50. It has a 50-day moving average of $24.12 and a 200-day moving average of $27.53. The company's current ratio is 10.40, with a quick ratio of 9.97 and a high debt-to-equity ratio of 365.37.
$QURE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 18, 2026, Barclays upgraded uniQure N.V. to a 'buy' rating with a price target of $65. Goldman Sachs maintained a 'hold' rating with a $46 target, while Leerink Partners and RBC Capital maintained their 'buy' ratings with targets of $70 and $65, respectively. The consensus among analysts is a 'strong buy', with a mean price target of $58.75 based on 11 analyst opinions.
About uniQure N.V.
uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands, focused on developing treatments for rare and severe diseases. Its key product, HEMGENIX, helps hemophilia B patients by enabling them to produce factor IX, reducing bleeding risk. The company is also advancing several gene therapy candidates, including AMT-130 for Huntington's disease, AMT-260 for epilepsy, and AMT-191 for Fabry disease. Led by CEO Matthew Kapusta, uniQure employs 221 people.
Bottom Line
Madhavan Balachandran's recent sale of uniQure shares is part of ongoing insider trading activity. uniQure's stock remains a focus for investors due to its significant institutional interest and varied analyst ratings. As always, these insider transactions and analyst opinions provide a backward-looking insight into the company's current standing.
Get uniQure N.V. alerts
New 13F filings, insider trades, and analyst moves on $QURE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.